Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03929822 · ClinicalTrials.gov registry record
Can Contrast-Enhanced Spectral Mammography Improve the Accuracy of a Diagnosis
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- 32
- Enrollment target
NCT03929822: Clinical Trial study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03929822 is a clinical trial that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03929822 was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether contrast-enhanced spectral mammography (CESM) may be able to reduce the number of unnecessary biopsies in women whose screening mammograms had abnormal findings.
Interventions
- DIAGNOSTIC_TEST Contrast-Enhanced Spectral Mammography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-04-23 |
| Est. Completion | 2023-01-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03929822
The ClinicalTrials.gov registry entry for NCT03929822 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Contrast-Enhanced Spectral Mammography is the first listed.
NCT03929822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03929822 about?
NCT03929822 is a clinical study titled "Can Contrast-Enhanced Spectral Mammography Improve the Accuracy of a Diagnosis". The purpose of this study is to test whether contrast-enhanced spectral mammography (CESM) may be able to reduce the number of unnecessary biopsies in women whose screening mammograms had abnormal findings.
What is the current status of trial NCT03929822?
This trial is currently terminated. The enrollment target is 32 participants. The study started on 2019-04-23. Estimated completion is 2023-01-19.
What interventions are being tested in trial NCT03929822?
The interventions under investigation include: Contrast-Enhanced Spectral Mammography (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03929822?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.